Results 21 to 30 of about 61,873 (295)
Metoclopramide in Gastroparesis: Its Mechanism of Action and Safety Profile
Gastrointestinal Disorders, 2023 Metoclopramide has been the cornerstone of gastroparesis management for the past 40 years as it is the only FDA-approved medication for gastroparesis. Other medications such as erythromycin and domperidone have been used off-label with variable efficacy.
M Ammar Kalas +4 more
doaj +1 more source
Schizophrenia Bulletin, 1993 Neuroleptic-induced tardive dyskinesia (TD) continues to be a serious problem in the psychopharmacology of schizophrenia. The overall mean prevalence of TD among chronically neuroleptic-treated patients is approximately 24 percent. The annual incidence in younger adults is 4 to 5 percent. Aging is a major risk factor for TD.
D V, Jeste, M P, Caligiuri
openaire +2 more sources
Metoclopramide Neurological Side Effects Screening; A Pharmacovigilence Study in Romanian Community Pharmacies [PDF]
, 2015 Background. Metoclopramide is a pharmacological agent frequently used in therapy against nausea and vomiting that can occur in indigestion, motion sickness, gastric ulcer, pyloric spasm and after surgery as a side effect of some anesthetics.
Junghină, Adrian +4 more
core +4 more sources
Maladaptive plasticity in levodopa-induced dyskinesias and tardive dyskinesias: old and new insights on the effects of dopamine receptor pharmacology. [PDF]
, 2014 Maladaptive plasticity can be defined as behavioral loss or even development of disease symptoms resulting from aberrant plasticity changes in the human brain.
Ahmed +58 more
core +2 more sources
Treatment Recommendations for Tardive Dyskinesia
Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2019 Background: Tardive dyskinesia is a movement disorder characterised by irregular, stereotyped, and choreiform movements associated with the use of antipsychotic medication. We aim to provide recommendations on the treatment of tardive dyskinesia. Methods:
L. Ricciardi +10 more
semanticscholar +1 more source
No association of a set of candidate genes on haloperidol side effects. [PDF]
, 2012 We previously investigated a sample of patients during an active phase of psychosis in the search for genetic predictors of haloperidol induced side effects.
De Ronchi, Diana +8 more
core +4 more sources
Consilium Medicum, 2021 Tardive dyskinesia is a group of hyperkinetic and hypokinetic movement disorders, following the administration of dopamine receptor-blocking drugs. The severity of these syndromes varies from soft forms to the development of life-degrading situations ...
Violetta A. Tolmacheva
doaj +1 more source
World Psychiatry, 2018 Tardive dyskinesia (TD) risk with D2/serotonin receptor antagonists or D2 receptor partial agonists (second‐generation antipsychotics, SGAs) is considered significantly lower than with D2 antagonists (first‐generation antipsychotics, FGAs).
Maren Carbon +3 more
semanticscholar +1 more source
Tardive dyskinesia on clozapine: A case report
South African Journal of Psychiatry, 2009 Antipsychotic-induced tardive dyskinesia is a potentially irremediable and debilitating condition with the onset most commonly associated with the use of first-generation antipsychotics.
Laila Asmal
doaj +1 more source
Neurologijos seminarai, 2020 Introduction. Tardive dyskinesia is a movement disorder that begins with exposure to dopamine receptor-blocking agents for at least a few months. These agents include most of antipsychotics, which are widely used to treat mental illness.
I. Pabarčiūtė , M. Karnickas
doaj +1 more source